Andrew Z. Wang
- Biomaterials top 0.05%
- Nanoparticle-Based Drug Delivery 68
- Biomedical Engineering top 0.1%
- Nanoplatforms for cancer theranostics 45
- Pharmaceutical Science top 0.2%
- Molecular Medicine top 1%
- Molecular Biology top 1%
- RNA Interference and Gene Delivery 26
-
- Immunotherapy and Immune Responses 23
-
- Cancer Cells and Metastasis 20
- Cancer Immunotherapy and Biomarkers 18
-
- Advanced Radiotherapy Techniques 18
-
- Radiation Therapy and Dosimetry 17
- Co-authors
- Omid C. FarokhzadRóbert LangerFrank GuJuliana M. ChanJoseph M. CasterYuanzeng MinLiangfang ZhangAleksandar F. Radovic‐Moreno
- Journals
- Chemical Reviews (1 paper)Proceedings of the National Academy of Sciences (3 papers)Journal of the American Chemical Society (1 paper)
- Partner nations
- United StatesChinaSouth Korea
In The Last Decade
Andrew Z. Wang
247 papers receiving 15.9k citations
Hit Papers
Peers
Comparison fields: 5 of 178
- Biomaterials 6.8k
- Biomedical Engineering 7.3k
- Pharmaceutical Science 987
- Molecular Medicine 433
- Molecular Biology 5.4k
Countries citing papers authored by Andrew Z. Wang
This map shows the geographic impact of Andrew Z. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Z. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Z. Wang more than expected).
Fields of papers citing papers by Andrew Z. Wang
This network shows the impact of papers produced by Andrew Z. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Z. Wang. The network helps show where Andrew Z. Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Andrew Z. Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 5 | |
| 5 | 2024 | 0 | |
| 6 | 2023 | 2 | |
| 7 | 2023 | 14 | |
| 8 | 2023 | 5 | |
| 9 | 2021 | 53 | |
| 10 | 2021 | 54 | |
| 11 | Silencing of Long Non-Coding RNA Colon Cancer-Associated Transcript 2 Inhibits the Growth and Metastasis of Gastric Cancer Through Blocking mTOR Signaling | 2020 | 1 |
| 12 | 2020 | 16 | |
| 13 | 2019 | 2 | |
| 14 | 2018 | 34 | |
| 15 | 2018 | 46 | |
| 16 | 2018 | 132 | |
| 17 | 2017 | 1 | |
| 18 | 2017 | 48 | |
| 19 | 2016 | 72 | |
| 20 | Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymersbreakdown → | 2008 | 577 |
About Andrew Z. Wang
Andrew Z. Wang is a scholar working on Biomaterials, Oncology and Radiation, having authored 268 papers that have together received 16.2k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (68 papers), Nanoplatforms for cancer theranostics (45 papers), RNA Interference and Gene Delivery (26 papers), Immunotherapy and Immune Responses (23 papers), Cancer Cells and Metastasis (20 papers), Advanced Radiotherapy Techniques (18 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Radiation Therapy and Dosimetry (17 papers). The work is most often cited by research in Biomaterials (6.8k citations), Biomedical Engineering (7.3k citations) and Pharmaceutical Science (987 citations). Andrew Z. Wang has collaborated with scholars based in United States, China and South Korea. Frequent co-authors include Omid C. Farokhzad, Róbert Langer, Frank Gu, Juliana M. Chan, Joseph M. Caster, Yuanzeng Min, Liangfang Zhang, Aleksandar F. Radovic‐Moreno, Michael J. Eblan and Edina C. Wang. Their work appears in journals such as Chemical Reviews, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.